Mizuho raised the firm’s price target on DexCom (DXCM) to $78 from $75 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion “under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Citi ups DexCom target, adds ‘upside 90-day catalyst watch’
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls
- DexCom upgraded to Overweight at Morgan Stanley with company turning corner
- DexCom upgraded to Overweight from Equal Weight at Morgan Stanley
- ServiceNow, Dexcom, Coinbase, Jumia, Keysight: Trending by Analysts